<i>Jak2V617F</i> Reversible Activation Shows an Essential Requirement for Jak2V617F in Myeloproliferative Neoplasms (MPNs)
Andrew Dunbar(Memorial Sloan Kettering Cancer Center), Ross L. Levine(Memorial Sloan Kettering Cancer Center), Mirko Farina(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Shoron Mowla(Memorial Sloan Kettering Cancer Center), Won Jun Kim(Kettering University), Michael R. Waarts(Cancer Services), Franco Izzo(Fred Hutch Cancer Center), Anthony R. Martinez Benitez(Memorial Sloan Kettering Cancer Center), Robert L. Bowman(University of Pennsylvania), Aaron D. Viny(Columbia University Irving Medical Center), Shira E. Eisman(Memorial Sloan Kettering Cancer Center), Emily Guzzardi(Memorial Sloan Kettering Cancer Center), Abbas Nazir(Memorial Sloan Kettering Cancer Center), Wenbin Xiao(Memorial Sloan Kettering Cancer Center), Richard P. Koche(Massachusetts General Hospital), Remie Houston(Memorial Sloan Kettering Cancer Center), Tanmay Mishra(Vellore Institute of Technology University), Robert M. Myers(Memorial Sloan Kettering Cancer Center), Abdul Karzai(Memorial Sloan Kettering Cancer Center), Wenbin An(Chinese Academy of Medical Sciences & Peking Union Medical College), Louise Cai(Memorial Sloan Kettering Cancer Center), Sheng F. Cai(Memorial Sloan Kettering Cancer Center), Dan A. Landau(Cornell University), Young Joo Park(Sutro Biopharma (United States)), Benjamin Wang(Memorial Sloan Kettering Cancer Center), Max Brodsky(Memorial Sloan Kettering Cancer Center), Julie Yang(Memorial Sloan Kettering Cancer Center), Inés Fernández-Maestre(Memorial Sloan Kettering Cancer Center)
Cited by 4
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k